ConductScience.org, home

Comparison · NCT04115319-deaths

SEP-363856 50 to 100 mg/Day vs Quetiapine XR 400 to 800 mg/Day: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. SEP-363856 50 to 100 mg/Day vs Quetiapine XR 400 to 800 mg/Day: deaths from any cause. Trial comparisons, record NCT04115319-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04115319-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0188wilson
Risk in group 2000.0363wilson
Risk difference, group 1 minus group 20-0.03630.0188newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1SEP-363856 50 to 100 mg/Day
Participants received flexible doses of SEP-363856 50 to 100 milligram per day (mg/day), orally, once daily (QD) up to Week 52. The dose was titrated up from 50 mg/day on Days 1 to 3, to 75 mg/day on Days 4 to 7. Beginning Day 8, the dose was adjusted within the range of 50 mg/day to 100 mg/day in 25 mg increments (i.e. 50, 75, or 100 mg/day) up to Week 52.
0201EG000
Group 2Quetiapine XR 400 to 800 mg/Day
Participants received flexible doses of quetiapine XR 300 to 800 mg/day, orally, QD up to Week 52. The dose was titrated up from 300 mg/day on Days 1 to 2, followed by 400 mg/day on Days 3 to 4, to 600 mg/day on Days 5 to 7. Beginning Day 8, the dose was adjusted within the range of 400 mg/day to 800 mg/day in 200 mg increments (i.e. 400, 600, or 800 mg/day) up to Week 52.
0102EG001

Harm

What it counts
Total, all-cause mortality
Time frame
From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)

Source ClinicalTrials.gov

Trial

Title
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
NCT number
NCT04115319
Phases
PHASE3
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Results first posted
2025-12-31

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04115319-deaths